A Study of Efficacy and Safety of Ianalumab in Previously Treated Patients With Warm Autoimmune Hemolytic Anemia

Last updated: February 13, 2025
Sponsor: Novartis Pharmaceuticals
Overall Status: Active - Recruiting

Phase

3

Condition

Anemia

Treatment

Placebo

Ianalumab

Clinical Study ID

NCT05648968
CVAY736O12301
2022-001773-31
2024-510635-21-00
  • Ages 18-100
  • All Genders

Study Summary

The purpose of this study is to evaluate efficacy and safety of ianalumab compared to placebo in patients with warm autoimmune hemolytic anemia, who failed at least one line of treatment.

Eligibility Criteria

Inclusion

Key Inclusion Criteria:

  • 18 years and older at time of signing consent

  • Patients with primary or secondary wAIHA documented by positive direct antiglobulintest specific for anti-IgG or anti-IgA, who had an insufficient response to, orrelapsed after at least one line of treatment, including patients with steroidresistance, dependence or intolerance

  • Hemoglobin concentration at screening and at Week 1 >=5 g/dL and <10 g/dL,associated with presence of symptoms related to anemia

  • The dose of supportive care must be stable for at least 4 weeks prior torandomization into the study

Exclusion

Key Exclusion Criteria:

  • wAIHA secondary to hematologic disease involving bone marrow (e.g., CLL) or anotherimmunologic disease requiring prohibited medication as per protocol. Patients withautoimmune diseases after wash-out from the treatments are allowed.

  • Presence of other forms of AIHA (cold or intermediate forms), Evans Syndrome orother cytopenias

  • Prior use of B-cell depleting therapy (e.g., rituximab) within 12 weeks prior torandomization, or without hematological response to the last course of B-celldepleting therapy

  • Neutrophils: <1000/mm3

  • Serum creatinine >1.5 × upper limit of normal (ULN)

  • Immunoglobulin G (IgG) <5g/L

  • Active viral, bacterial or other infections (including tuberculosis and SARS-CoV-2)requiring systemic treatment at time of screening, or history of recurrentclinically significant infection

  • Positivity for hepatitis C virus, hepatitis B surface antigen (HBsAg), or hepatitisB core antibody (HBcAb). HBcAb positive patients can be enrolled if HBsAg negative,HBV DNA negative, no pre-existing liver fibrosis is present and antiviralprophylaxis is given.

  • Known history of primary or secondary immunodeficiency, or a positive human immunedeficiency virus (HIV) test result

  • Live or live-attenuated vaccination within 4 weeks before randomization

  • History of splenectomy

Other protocol-defined Inclusion/Exclusion may apply.

Study Design

Total Participants: 90
Treatment Group(s): 2
Primary Treatment: Placebo
Phase: 3
Study Start date:
December 30, 2022
Estimated Completion Date:
May 02, 2029

Study Description

The primary objective is to demonstrate that either dose of ianalumab induces a durable hemoglobin response compared to placebo in patients with wAIHA.

The key secondary objective is to demonstrate that either dose of ianalumab maintains a durable hemoglobin response that is sustained beyond end of the treatment period, compared to placebo.

Participants are randomized to two different doses of ianalumab or placebo. Participants who were assigned to placebo arm and not responding to treatment may be treated with open label ianalumab using the higher dose.

The investigational treatment will be supplied in a double-blinded manner. For the open label period, ianalumab will be provided in an open label manner.

In addition to the randomized treatment (ianalumab or placebo), specific supportive care medication as defined in the protocol is allowed. If clinically indicated (e.g., to ensure patient safety), the treating physician may also administer rescue medication.

The study consists of the treatment period, efficacy and safety follow-up periods. The visit frequency will be every other week during the treatment and primary endpoint follow up period; for safety monitoring monthly during the first 20 weeks after last dose and afterwards quarterly up to 2 years from the last dose. For participants in durable response, additional visits for efficacy will occur monthly during the first 2 years after the last dose, and afterwards quarterly until loss of response or end of study, latest until up to 39 months post randomization of the last participant.

Connect with a study center

  • Novartis Investigative Site

    Caba, Buenos Aires C1414DRK
    Argentina

    Active - Recruiting

  • Novartis Investigative Site

    Ciudad Autonoma de Bs As, Buenos Aires C1015ABO
    Argentina

    Active - Recruiting

  • Novartis Investigative Site

    Buenos aires, C1039AAC
    Argentina

    Active - Recruiting

  • Novartis Investigative Site

    Canberra, Australian Capital Territory 2605
    Australia

    Active - Recruiting

  • Novartis Investigative Site

    Fitzroy, Victoria 3065
    Australia

    Active - Recruiting

  • Novartis Investigative Site

    Melbourne, Victoria 3004
    Australia

    Active - Recruiting

  • Novartis Investigative Site

    Prahran, Victoria 3181
    Australia

    Site Not Available

  • Novartis Investigative Site

    Guangzhou, Guangdong 510515
    China

    Active - Recruiting

  • Novartis Investigative Site

    Wuhan, Hubei 430022
    China

    Active - Recruiting

  • Novartis Investigative Site

    Suzhou, Jiangsu 215004
    China

    Active - Recruiting

  • Novartis Investigative Site

    Kunming, Yunnan 650101
    China

    Active - Recruiting

  • Novartis Investigative Site

    Hangzhou, Zhejiang 310003
    China

    Active - Recruiting

  • Novartis Investigative Site

    Dalian, 116000
    China

    Active - Recruiting

  • Novartis Investigative Site

    Tianjin, 300052
    China

    Active - Recruiting

  • Novartis Investigative Site

    Blois Cedex, 41000
    France

    Active - Recruiting

  • Novartis Investigative Site

    Caen, 14033
    France

    Active - Recruiting

  • Novartis Investigative Site

    Creteil, 94010
    France

    Active - Recruiting

  • Novartis Investigative Site

    Le Mans, 72000
    France

    Active - Recruiting

  • Novartis Investigative Site

    Lille, 59037
    France

    Active - Recruiting

  • Novartis Investigative Site

    Lille Cedex, 59 037
    France

    Site Not Available

  • Novartis Investigative Site

    Nantes Cedex 1, 44093
    France

    Active - Recruiting

  • Novartis Investigative Site

    Nice, 06202
    France

    Active - Recruiting

  • Novartis Investigative Site

    Nice Cedex, 06202
    France

    Site Not Available

  • Novartis Investigative Site

    Toulouse, 31059
    France

    Active - Recruiting

  • Novartis Investigative Site

    Vandoeuvre Les Nancy, 54511
    France

    Active - Recruiting

  • Novartis Investigative Site

    Dresden, 01307
    Germany

    Active - Recruiting

  • Novartis Investigative Site

    Essen, 45147
    Germany

    Active - Recruiting

  • Novartis Investigative Site

    Frankfurt, 60590
    Germany

    Active - Recruiting

  • Novartis Investigative Site

    Giessen, 35392
    Germany

    Active - Recruiting

  • Novartis Investigative Site

    Greifswald, 17475
    Germany

    Site Not Available

  • Novartis Investigative Site

    Hannover, 30161
    Germany

    Active - Recruiting

  • Novartis Investigative Site

    Debrecen, 4032
    Hungary

    Active - Recruiting

  • Novartis Investigative Site

    Madurai, TamilNadu 625107
    India

    Site Not Available

  • Novartis Investigative Site

    Hyderabad, Telangana 500082
    India

    Site Not Available

  • Novartis Investigative Site

    Lucknow, Uttar Pradesh 226014
    India

    Site Not Available

  • Novartis Investigative Site

    New Delhi, 110029
    India

    Site Not Available

  • Novartis Investigative Site

    Afula, 1834111
    Israel

    Active - Recruiting

  • Novartis Investigative Site

    Kfar Saba, 44281
    Israel

    Active - Recruiting

  • Novartis Investigative Site

    Petach Tikva, 4941492
    Israel

    Active - Recruiting

  • Novartis Investigative Site

    Zerifin, 7030000
    Israel

    Active - Recruiting

  • Novartis Investigative Site

    Avellino, AV 83100
    Italy

    Active - Recruiting

  • Novartis Investigative Site

    Bari, BA 70124
    Italy

    Active - Recruiting

  • Novartis Investigative Site

    Milano, MI 20100
    Italy

    Active - Recruiting

  • Novartis Investigative Site

    Bassano Del Grappa, Vicenza 36061
    Italy

    Active - Recruiting

  • Novartis Investigative Site

    Novara, 28100
    Italy

    Active - Recruiting

  • Novartis Investigative Site

    Narita, Chiba 286-8523
    Japan

    Active - Recruiting

  • Novartis Investigative Site

    Matsuyama-city, Ehime 790-0024
    Japan

    Active - Recruiting

  • Novartis Investigative Site

    Fukuoka city, Fukuoka 812-8582
    Japan

    Active - Recruiting

  • Novartis Investigative Site

    Gifu-city, Gifu 501-1194
    Japan

    Active - Recruiting

  • Novartis Investigative Site

    Kobe, Hyogo 650-0047
    Japan

    Active - Recruiting

  • Novartis Investigative Site

    Kobe-city, Hyogo 650-0047
    Japan

    Site Not Available

  • Novartis Investigative Site

    Isehara, Kanagawa 259-1193
    Japan

    Active - Recruiting

  • Novartis Investigative Site

    Suita, Osaka 565 0871
    Japan

    Active - Recruiting

  • Novartis Investigative Site

    Itabashi-ku, Tokyo 173-8610
    Japan

    Active - Recruiting

  • Novartis Investigative Site

    Shinjuku Ku, Tokyo 160-0023
    Japan

    Active - Recruiting

  • Novartis Investigative Site

    Shinjuku-ku, Tokyo 160-0023
    Japan

    Site Not Available

  • Novartis Investigative Site

    Aomori, 030 8553
    Japan

    Active - Recruiting

  • Novartis Investigative Site

    Yamagata, 990 9585
    Japan

    Active - Recruiting

  • Novartis Investigative Site

    Kuching, Sarawak 93586
    Malaysia

    Site Not Available

  • Novartis Investigative Site

    Johor Bahru, 80100
    Malaysia

    Completed

  • Novartis Investigative Site

    Kuala Lumpur, 56000
    Malaysia

    Active - Recruiting

  • Novartis Investigative Site

    Penang, 10050
    Malaysia

    Active - Recruiting

  • Novartis Investigative Site

    Pulau Pinang, 10990
    Malaysia

    Active - Recruiting

  • Novartis Investigative Site

    Selangor, 68000
    Malaysia

    Active - Recruiting

  • Novartis Investigative Site

    Bucuresti, 013975
    Romania

    Active - Recruiting

  • Novartis Investigative Site

    Singapore, 119074
    Singapore

    Active - Recruiting

  • Novartis Investigative Site

    Barcelona, Catalunya 08035
    Spain

    Active - Recruiting

  • Novartis Investigative Site

    Murcia, 30008
    Spain

    Active - Recruiting

  • Novartis Investigative Site

    Taoyuan, 33305
    Taiwan

    Active - Recruiting

  • Novartis Investigative Site

    Bangkok, 10700
    Thailand

    Site Not Available

  • Novartis Investigative Site

    Chiang Mai, 50200
    Thailand

    Active - Recruiting

  • Novartis Investigative Site

    Birmingham, B15 2TH
    United Kingdom

    Active - Recruiting

  • Novartis Investigative Site

    Leeds, LS1 3EX
    United Kingdom

    Active - Recruiting

  • Novartis Investigative Site

    London, W12 0HS
    United Kingdom

    Active - Recruiting

  • University of Colorado Anschutz

    Aurora, Colorado 80045
    United States

    Active - Recruiting

  • Napa Research

    Margate, Florida 33063
    United States

    Active - Recruiting

  • NorthShore University Health System

    Evanston, Illinois 60201
    United States

    Active - Recruiting

  • Parkview Research Center

    Fort Wayne, Indiana 46845
    United States

    Active - Recruiting

  • Parkview Research Center .

    Fort Wayne, Indiana 46845
    United States

    Active - Recruiting

  • Michigan Center of Medical Research

    Farmington Hills, Michigan 48334
    United States

    Active - Recruiting

  • University of Minnesota Med Center

    Minneapolis, Minnesota 55455
    United States

    Active - Recruiting

  • Summit Health

    Florham Park, New Jersey 07932
    United States

    Active - Recruiting

  • Inspira Medical Cent Mullica Hill

    Mullica Hill, New Jersey 08062
    United States

    Active - Recruiting

  • Montefiore Medical Center

    Bronx, New York 10461
    United States

    Active - Recruiting

  • Montefiore Medical Center .

    Bronx, New York 10461
    United States

    Active - Recruiting

  • Brody School of Medicine

    Greenville, North Carolina 27834
    United States

    Active - Recruiting

  • Gabrail Cancer Center

    Canton, Ohio 44718
    United States

    Active - Recruiting

  • STAT Research Inc

    Dayton, Ohio 45402
    United States

    Active - Recruiting

  • STAT Research Inc Premier Clin Res LLC STAT Res

    Dayton, Ohio 45402
    United States

    Active - Recruiting

  • Texas Oncology-Baylor Scott and White

    Dallas, Texas 75231
    United States

    Active - Recruiting

  • Baylor College Of Medicine

    Houston, Texas 77030
    United States

    Active - Recruiting

  • Fred Hutchinson Cancer Center

    Seattle, Washington 98109
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.